ProShare Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

ProShare Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,401	Closed	-$77K	–	1772
2018 Q3	$77K	Sell	1,401 -24	-2%	-$1.53K	﹤0.01%	1700
2018 Q2	$102K	Sell	1,425 -97	-6%	-$6.85K	﹤0.01%	1707
2018 Q1	$93K	Sell	1,522 -241	-14%	-$21.2K	﹤0.01%	1641
2017 Q4	$222K	Buy	+1,763	New	+$226K	﹤0.01%	1590
2016 Q4	–	Sell	-1,337	Closed	-$102K	–	1764
2016 Q3	$102K	Sell	1,337 -248	-16%	-$19.9K	﹤0.01%	1416
2016 Q2	$136K	Buy	1,585 +19	+1%	+$1.74K	﹤0.01%	1491
2016 Q1	$145K	Sell	1,566 -166	-10%	-$16.6K	﹤0.01%	1474
2015 Q4	$347K	Buy	1,732 +171	+11%	+$34.1K	﹤0.01%	1225
2015 Q3	$233K	Sell	1,561 -110	-7%	-$80.7K	﹤0.01%	1243
2015 Q2	$1.59M	Buy	1,671 +184	+12%	+$150K	0.02%	586
2015 Q1	$1.09M	Buy	1,487 +192	+15%	+$144K	0.01%	805
2014 Q4	$1.03M	Buy	+1,295	New	+$697K	0.01%	835
2014 Q3	–	Sell	-537	Closed	-$145K	–	2401
2014 Q2	$145K	Sell	537 -173	-24%	-$37.1K	﹤0.01%	2276
2014 Q1	$155K	Buy	+710	New	+$198K	﹤0.01%	2603

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ProShare Advisors's TTPH Position: Q4 2018 in Review

ProShare Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2018, closing a stake of 1,401 shares — an estimated $77K sold.

ProShare Advisors first reported a position in TTPH in Q1 2014 and held it in 14 quarters. The position peaked at $1.59M in Q2 2015. 86 funds tracked by Wall St. Rank hold TTPH as of Q4 2018.

ProShare Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
ProShare Advisors sold 1,401 Tetraphase Pharmaceuticals, Inc. shares in Q4 2018, an estimated $77K.
ProShare Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 14 quarters.
ProShare Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $1.59M in Q2 2015.
86 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.